Benjamin Hickey
CIK 1753055 · President, RayzeBio Org. · last filed 2026-03-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MRTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
ROUTE 206 AND PROVINCE LINE ROAD
PRINCETON, NJ 08543
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BMY | President, RayzeBio Org. | 18,344 | $61.75 | $1.13M | -$3.7K | 9 | 2026-03-12 |
| MURAV | Director | — | — | — | $0 | 5 | 2025-12-05 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | EVP, Chief Commercial Officer | 0 | $58.70 | $0 | -$1.85M | 16 | 2024-01-23 |
| Surface Oncology, Inc. (SURF) Delisted | Director | — | $1.07 | — | $0 | 2 | 2022-06-10 |
| HALOZYME THERAPEUTICS, INC. (HTI) Delisted | SVP, Chief Commerical Officer | 13,226 | — | — | $0 | 3 | 2019-10-01 |
Recent Filings · Page 2 of 4
35 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-03 | MURAV | Grant (A) | — | $0 | EDGAR |
| 2024-03-12 | BMY | Grant (A) | — | $0 | EDGAR |
| 2024-03-04 | BMY | Grant (A) | — | $0 | EDGAR |
| 2024-01-23 | Mirati Therapeutics, Inc. (MRTX) Delisted | Disp (D) | −117,028 | $0 | EDGAR |
| 2024-01-18 | Mirati Therapeutics, Inc. (MRTX) Delisted | Sell (S) | −1,597 | -$94.3K | EDGAR |
| 2024-01-09 | Mirati Therapeutics, Inc. (MRTX) Delisted | Sell (S) | −2,090 | -$123.1K | EDGAR |
| 2024-01-03 | Mirati Therapeutics, Inc. (MRTX) Delisted | Grant (A) | +17,021 | $1000.0K | EDGAR |
| 2023-12-18 | MURAV | Grant (A) | — | $0 | EDGAR |
| 2023-12-14 | Mirati Therapeutics, Inc. (MRTX) Delisted | Sell (S) | −2,220 | -$125.8K | EDGAR |
| 2023-08-10 | Mirati Therapeutics, Inc. (MRTX) Delisted | Grant (A) | +22,297 | $825.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.